HUTCHMED (China) Ltd Files March 2024 6-K Report
Ticker: HMDCF · Form: 6-K · Filed: Mar 22, 2024 · CIK: 1648257
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
HUTCHMED (China) Ltd filed its March 6-K, confirming 20-F annual report filings.
AI Summary
HUTCHMED (China) Limited filed a Form 6-K on March 22, 2024. This report is for the month of March 2024 and indicates the company files annual reports under Form 20-F. The company's principal executive offices are located in Hong Kong.
Why It Matters
This filing provides routine updates for HUTCHMED (China) Limited, a foreign private issuer, to the SEC, ensuring transparency for investors regarding their reporting obligations.
Risk Assessment
Risk Level: low — This is a routine 6-K filing, typically used for ongoing reporting by foreign private issuers, and does not contain specific material events or financial disclosures.
Key Players & Entities
- HUTCHMED (China) Limited (company) — Registrant
- 20240322 (date) — Filing Date
- Hong Kong (location) — Principal Executive Offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company has made or is required to make public in its home country, filed with or made to any stock exchange, or distributed to its security holders.
Which form does HUTCHMED (China) Limited use for its annual reports?
HUTCHMED (China) Limited indicates it files annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is March 22, 2024.
Where are HUTCHMED (China) Limited's principal executive offices located?
The principal executive offices of HUTCHMED (China) Limited are located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
What is the Commission File Number for HUTCHMED (China) Limited?
The Commission File Number for HUTCHMED (China) Limited is 001-37710.
Filing Stats: 176 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2024-03-22 06:06:15
Filing Documents
- hcm-20240322x6k.htm (6-K) — 19KB
- hcm-20240322xex99d1.htm (EX-99.1) — 23KB
- hcm-20240322xex99d1001.jpg (GRAPHIC) — 5KB
- 0001648257-24-000023.txt ( ) — 50KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Press release relating to initiation of registration stage of the ESLIM-02 Phase II/III trial of sovleplenib for warm antibody autoimmune hemolytic anemia in China 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: March 22, 2024 3